In the last trading session, 1.44 million Revance Therapeutics Inc (NASDAQ:RVNC) shares changed hands as the company’s beta touched 0.87. With the company’s per share price at $7.47 changed hands at $0.2 or 2.68% during last session, the market valuation stood at $655.50M. RVNC’s last price was a discount, traded about -408.43% off its 52-week high of $37.98. The share price had its 52-week low at $5.72, which suggests the last value was 23.43% up since then. When we look at Revance Therapeutics Inc’s average trading volume, we note the 10-day average is 2.6 million shares, with the 3-month average coming to 2.11 million.
Analysts gave the Revance Therapeutics Inc (RVNC) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.42. If we narrow down to specifics, the data shows that 0 out of 12 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended RVNC as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight. Revance Therapeutics Inc’s EPS for the current quarter is expected to be -$0.82.
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Instantly RVNC was in green as seen at the end of in last trading. With action 28.49%, the performance over the past five days has been green. The jump to weekly highs of 7.63 on Monday, 11/20/23 added 2.68% to the stock’s daily price. The company’s shares are showing year-to-date downside of -59.56%, with the 5-day performance at 28.49% in the green. However, in the 30-day time frame, Revance Therapeutics Inc (NASDAQ:RVNC) is -11.76% down. Looking at the short shares, we see there were 12.93 million shares sold at short interest cover period of 7.22 days.
The consensus price target for the stock as assigned by Wall Street analysts is $26.91, meaning bulls need an upside of 72.24% from its current market value. According to analyst projections, RVNC’s forecast low is $9.00 with $42.00 as the target high. To hit the forecast high, the stock’s price needs a -462.25% plunge from its current level, while the stock would need to soar -20.48% for it to hit the projected low.
Revance Therapeutics Inc (RVNC) estimates and forecasts
Data shows that the Revance Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -77.04% over the past 6 months, a 19.59% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Revance Therapeutics Inc will rise 54.90%, while the growth in revenue is estimated to hit 21.60% for the next quarter. Year-over-year growth is forecast to reach 74.20% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of $67.01 million. 4 analysts are of the opinion that Revance Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $68.19 million. The company’s revenue for the corresponding quarters a year ago was $49.92 million and $49.33 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 34.20%. The estimates for the next quarter sales put growth at 38.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.10%. The 2023 estimates are for Revance Therapeutics Inc earnings to increase by 31.07%, but the outlook for the next 5-year period is at 11.60% per year.
Revance Therapeutics Inc is expected to release its next quarterly earnings report on November 08.
Revance Therapeutics Inc (NASDAQ:RVNC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.44% of Revance Therapeutics Inc shares while 97.12% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.55%. There are 97.12% institutions holding the Revance Therapeutics Inc stock share, with Capital World Investors the top institutional holder. As of Jun 29, 2023, the company held 10.89% of the shares, roughly 9.57 million RVNC shares worth $242.34 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 7.42% or 6.53 million shares worth $165.19 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Smallcap World Fund and Vanguard Total Stock Market Index Fund. With 6.38 million shares estimated at $161.44 million under it, the former controlled 7.25% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.91% of the shares, roughly 2.56 million shares worth around $64.77 million.